Authors

Brittany F. Lees, MD

Latest:

Dr. Lees on the Utility of Genetic Testing in Ovarian Cancer

Brittany F. Lees, MD, discusses the utility of genetic and genomic testing in ovarian cancer.

Renee Saliby, MD

Latest:

Dr Saliby on the Correlation Between Intermediate End Points and OS in RCC

Renee Saliby, MD, MSc, discusses the investigation of the correlation between intermediate end points and OS in metastatic renal cell carcinoma.

Pratibha Binder, MD

Latest:

Dr. Binder on the Use of Immune Checkpoint Inhibitors in Endometrial Cancer Treatment

Pratibha Binder, MD, discusses how the introduction of novel immune checkpoint inhibitors into frontline treatment strategies could ameliorate unmet needs in endometrial cancer.

Hannah Goulart, MD

Hannah Goulart, MD, is a hematology oncology fellow at The University of Texas MD Anderson Cancer Center

Latest:

Dr Goulart on the Efficacy of Frontline Blinatumomab Plus Ponatinib in Ph+ B-ALL

Hannah Goulart, MD, discusses the use of first-line blinatumomab plus ponatinib in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia.

Peter Schmid, FRCP, MD, PhD

Latest:

Schmid Summarizes Updates in HER2-Positive Breast Cancer Management

Dr Schmid discusses considerations for applying recent data updates in HER2-positive breast cancer management to clinical practice.

Mylin A. Torres, MD

Latest:

Dr Torres on Treatment With ADCs in Breast Cancer

Mylin A. Torres, MD, discusses using antibody-drug conjugates (ADCs) to treat patients with breast cancer.

Pule Wang, MD

Pule Wang, MD, is a radiation oncology resident in the Department of Radiation Oncology at City of Hope in Duarte, California.

Latest:

Dr Wang on the Safety Profile of CNS Bridging Radiotherapy Prior to CAR T in B-Cell Lymphoma

Pule Wang, MD, discusses safety data with CNS bridging radiotherapy before CAR T in B-cell lymphoma.

Alessandro Gronchi, MD

Latest:

Dr. Gronchi on the Results of the TRASTS Trial in Soft Tissue Sarcoma

Alessandro Gronchi, MD, discusses the results of the phase 2 TRASTS trial in soft tissue sarcoma.

Daniel Keifenheim, PhD

Latest:

Novel Tubulin-Targeting Therapies Make Headway

Clinical findings have recently been reported for 2 of the more advanced emerging tubulin-targeting agents, VERU-111 and plinabulin.

Tim Cortese

Latest:

First-Line Disitamab Vedotin Plus Toripalimab Yields Survival Advantage in HER2+ Advanced Urothelial Cancer

Frontline disitamab vedotin plus toripalimab significantly improved PFS and OS in HER2-expressing locally advanced or metastatic urothelial carcinoma.

Kent Hoskins, MD

Latest:

Dr. Hoskins on the Impact of Race on Breast Cancer Outcomes

Kent Hoskins, MD, discusses the impact of race on breast cancer outcomes.

Emily C. Ayers, MD

Latest:

Dr. Ayers on the Evolving Treatment Landscape in CLL

Emily C. Ayers, MD, hematologist/oncologist, assistant professor, University of Virginia Health, discusses the evolving treatment landscape in chronic lymphocytic leukemia.

Caron A. Jacobson, MD, MMSc

Latest:

Looking Ahead to the Future of CAR T Therapy for B-Cell Lymphoma

Panelists discuss how CAR T therapy represents the best curative option for relapsed B-cell lymphoma and how community oncologists must prepare for the inevitable expansion of cellular therapies across multiple disease areas.

Eleonora Dondossola, PhD

Latest:

Dr Dondossola on the Importance of Studying Bone Metastasis in RCC

Eleonora Dondossola, PhD, discusses the importance of studying bone metastasis in RCC and other genitourinary cancers.

Brian C. Grieb, MD, PhD

Latest:

Dr Grieb on the Need for Novel Biomarkers in CRC

Brian C. Grieb, MD, PhD, discusses unmet needs for patients with colorectal cancer, including the identification of novel pan-CRC biomarkers for drug development.

Theresa Medina, MD

Theresa Medina MD

Latest:

Dr Medina on the Long-Term Efficacy and Safety of Lifileucel TIL Therapy in Advanced Melanoma

Theresa Medina, MD, discusses the long-term efficacy and safety of lifileucel TIL therapy in advanced melanoma.

Jeffrey Laurence, MD, Weill Cornell Medicine

Latest:

Narsoplimab Trial Results

The panel of transplant experts discuss the results of the phase 2 trial of narsoplimab and the pending FDA approval of this agent for treatment of transplant-associated of thrombotic microangiopathy.

John P. Sfakianos, MD

Latest:

Dr Sfakianos on Addressing Unmet Needs With Intravesical Mitomycin in Recurrent, Low-Grade, Intermediate-Risk NMIBC

John P. Sfakianos, MD, discusses the rationale for evaluating mitomycin intravesical solution in recurrent, low-grade, intermediate-risk NMIBC.

Aatur D. Singhi, MD, PhD

Latest:

Dr. Singhi on the Importance of Multidisciplinary Care With Pathologists in Cancer

Aatur D. Singhi, MD, PhD, discusses the importance of facilitating multidisciplinary conversations that include pathologists in cancer care.

Asim V. Farooq, MD, University of Chicago Medical Center

Latest:

Influencing Factors to Initially Targeting BCMA in MM